OOIR: Observatory of International Research

Papers

(The H4-Index of British Journal of Clinical Pharmacology is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
	75
Issue Information	68
Issue Highlights	65
Pharmacokinetics, safety and efficacy study in pregnancy and existing cumulative data/evidence to support clinical use and labelling of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in pre	58
Effect of oral clonidine on pain reduction in patients with opioid use disorder in the emergency department: A randomized clinical trial	56
Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population	55
Pregabalin poisoning: Evaluation of dose‐toxicity relationship	55
Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial	54
Insights from a pharmacometric analysis of HDMTX in adults with cancer: Clinically relevant covariates for application in precision dosing	53
Case report: Dolutegravir dosing post‐Roux‐en‐Y gastric bypass surgery	51
Drug reaction with eosinophilia and systemic symptoms induced by paclitaxel, a rare combination	43
Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’	42
Intranasal vitamin B₁₂ administration in elderly patients: A randomized controlled comparison of two dosage regimens	41
Comparison of the Liverpool Causality Assessment Tool vs. the Naranjo Scale for predicting the likelihood of an adverse drug reaction: A retrospective cohort study	41
Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects	40
Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real‐world study based on the United States Food and Drug Administration Adverse Event Reporting System database	40
Sensitivity of estimated tacrolimus population pharmacokinetic profile to assumed dose timing and absorption in real‐world data and simulated data	38
Triple antithrombotic therapy and dual therapy – What is the evidence base?	38
Therapeutic drug monitoring of thiopurines: Effect of reduced 6‐thioguanine nucleotide target levels in inflammatory bowel disease patients	36
Quantification of sertraline maternal/fetal ratio and amniotic fluid concentration using a pregnancy physiologically based pharmacokinetic model	35
Postoperative ileus after digestive surgery: Network meta‐analysis of pharmacological intervention	35
Prospective evaluation of pregnancy outcomes after gestational exposure to prazosin	34
Antidepressants are not safe during pregnancy and in women of child‐bearing age	34
Modelling the progression of illicit substance use patterns from real‐world evidence	33
Model‐based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non‐complicated methicillin‐resistant staphylococcus aureus infection	32

Serum uric acid lowering mediated by glucagon‐like peptide‐1 receptor agonists: Emerging considerations	32
Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry	30
Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity	30
Older adults' adherence to medications and willingness to deprescribe: A substudy of a randomized clinical trial	30
Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers	30